Clinical pharmacokinetics of stavudine

Clinical Pharmacokinetics

Volumn 33, Issue 4, 1997, Pages 276-284

  Rana, Khurram Z ^a   Dudley, Michael N ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b Microcide Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AGE; CEREBROSPINAL FLUID; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PENETRATION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PLACENTA; PRIORITY JOURNAL; REVIEW; TOTAL BODY WATER;

EID: 0030952601     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199733040-00003     Document Type: Review

References (32)

1. Baba M, Pauwels R, Herdewijn, et al. Both 2′,3′-dideoxythymidinene and its 2′,3′unsaturated derivative (2′,3′-dideoxythymidine) are potent and selective inhibitors of human immunodeficiency virus in vitro. Biochemistry 1987; 142: 128-34
2. Lin TS, Schinazi RF, Prusoff WH, et al. Potent and selective in vitro activity of 3′deoxythymidine-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol 1987; 36: 2713-8
3. August EM, Marangiu MB, Lin TS, et al. Initial studies on the cellular pharmacology of 3′-deoxythymidin-2′-ene (d4T): a potent and selective inhibitor of human immunodeficiency virus. Biochem Pharmacol 1988; 33: 4419-22
4. Balzarini JP, Herdewijin P, De Clereq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989; 264: 6127-33
5. Browne MJ, Mayer KH, Chafee SBD, et al. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993; 167: 21-9
6. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials Proun 089. J Infect Dis 1995; 171 Suppl. 2: S123-30
7. Skowron G. Biologic effects and safety of stavudine: overview of phase I and II clinical trials. J Infect Dis 1995; 171 Suppl. 2: S113-7
8. Ho H, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989; 33: 844-9
9. Dudley MM, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-5
10. Seifert RD, Stewart MB, Sramek JJ, et al. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients. Br J Clin Pharmacol 1994; 38: 405-10
11. Kaul S, Mumrnaneni V, Barbhaiya RH. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations. Biopharm Drug Dispos 1995; 16: 125-36
12. Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247-52
13. Yarchoan R, Mitsuya H, Myers C, et al. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726-38
14. Blum MR, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85: 189-94
15. Hartman NR, Yarchoan R, Pluda JM, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47: 647-54
16. Klecker RW, Collins JM, Yarchoan RC, et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988; 28: 837-42
17. Horton CM, Dudley MN, Kaul S, et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 1995; 39: 2309-15
18. August EM, Birks EM, Prusoff WH. 3′-Deoxythymidin-2′-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol Pharmacol 1991; 39: 246-9
19. Dudley MN. Clinical pharmacokinetics of nucleoside anti-retroviral agents. J Infect Dis 1995; 171 Suppl. 2: S99-112
20. Cretton EM, Zhou Z, Kidd LB, et al. In vitro and in vivo disposition of metabolism of 3′-deoxy-2′,3′-didehydriothymidine. Antimicrob Agents Chemother 1993; 37: 1816-25
21. Kline MW, Fletcher CV, Federeci ME, et al. Combination therapy with stavudine and didanosine in children with advanced immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996; 97: 886-90
22. Dudley MN, Horton C, Kaul S, et al. Integrated pharmacokinetic/pharmacodynamic model for analysis of changes in CD4 lymphocytes during antiretroviral therapy [abstract]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; American Society of Microbiology; 1992 Oct 11-14; Anaheim, CA. Washington, DC: American Society of Microbiology, 1992: 205
23. Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995; 171 Suppl. 2: S131-9
24. Griffith BP, Brett-Smith H, Kim G, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune-complex-dissociated antigenemia. J Infect Dis 1996; 173: 1252-5
25. Katlama C, Molina JM, Rozenbaum W, et al. Stavudine in HIV infected patients with CD4 > 350/mm3: results of a double- blind randomized placebo-controlled study [abstract]. In: Programs and abstracts of the 3rd Retroviruses and Opportunistic Infections. Infectious Diseases Society of America; 1996 Jan 28-Feb 1; Washington, DC: 196
26. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infecled, zidovudine-experienced patients. Ann Intern Med 1997; 126: 355-63
27. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962-9
28. BHIVA guidelines coordinating committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-92
29. Lambert JS, Seidlin M, Reichrnan RC, et al. 2′,3′-dideoxyinosinc (ddl) in patients with the acquired immondeficiency syndrome or AIDS-related complex. N Engl J Med 1990; 322: 1333-4
30. Cooley TP, Kunches LM, Suunders CA, et al. Once-daily administration of 2′,3′-dideoxyinosine (ddl) in patients with the acquired immunodeficiency syndrome or AIDS related complex. N Engl J Med 1990; 322: 1340-5
31. Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988; 1: 76-81
32. Merigan TC, Skowron G, Bozette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989; 110: 189-94